|
1
|
Globocan 2020, . New Global Cancer Data.
Uicc.org. 2021.https://www.uicc.org/news/globocan-2020-new-global-cancer-dataSeptember
18–2021
|
|
2
|
Al Jishi T and Sergi C: Current
perspective of diethylstilbestrol (DES) exposure in mothers and
offspring. Reprod Toxicol. 71:71–77. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Adcock R, Cuzick J, Hunt WC, McDonald RM
and Wheeler CM; New Mexico HPV Pap Registry Steering Committee, :
Role of HPV genotype, multiple infections, and viral load on the
risk of high-grade cervical Neoplasia. Cancer Epidemiol Biomarkers
Prev. 28:1816–1824. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Doorbar J, Egawa N, Griffin H, Kranjec C
and Murakami I: Human papillomavirus molecular biology and disease
association. Rev Med Virol. 25 (Suppl):S2–S23. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Galloway D and Laimins L: Human
papillomaviruses: Shared and distinct pathways for pathogenesis.
Cur Opin Virol. 14:87–92. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Plummer M, de Martel C, Vignat J, Ferlay
J, Bray F and Franceschi S: Global burden of cancers attributable
to infections in 2012: A synthetic analysis. Lancet Glob Health.
4:e609–e616. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wagner M, Bennetts L, Patel H, Welner S,
de Sanjose S and Weiss T: Global availability of data on HPV
genotype-distribution in cervical, vulvar and vaginal disease and
genotype-specific prevalence and incidence of HPV infection in
females. Infect Agent Cancer. 10:132015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yuan Y, Cai X, Shen F and Ma F: HPV
post-infection microenvironment and cervical cancer. Cancer Lett.
497:243–254. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cohen O, Schejter E, Agizim R, Schonman R,
Chodick G, Fishman A and Hershko Klement A: Postcoital bleeding is
a predictor for cervical dysplasia. PLoS One. 14:e02173962019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Reed N, Balega J, Barwick T, Buckley L,
Burton K, Eminowicz G, Forrest J, Ganesan R, Harrand R, Holland C,
et al: British Gynaecological Cancer Society (BGCS) cervical cancer
guidelines: Recommendations for practice. Eur J Obstet Gynecol
Reprod Biol. 256:433–465. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Issa Z, Aloan H and Al Niyazee A: Accuracy
of Pap smear in cervical cancer screening. World Family Med J.
17:16–20. 2019. View Article : Google Scholar
|
|
12
|
Johnson CA, James D, Marzan A and Armaos
M: Cervical cancer: An overview of pathophysiology and management.
Semin Oncol Nurs. 35:166–174. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pkhakadze G, Bokhua Z, Asatiani T,
Muzashvili T and Burkadze G: Evaluation of the risk of cervical
intraepithelial neoplasia progression based on cell proliferation
index, epithelial-mesenchymal transition and co-infections.
Georgian Med News. 178–184. 2020.PubMed/NCBI
|
|
14
|
Bhatla N, Aoki D, Sharma DN and
Sankaranarayanan R: Cancer of the cervix Uteri. Int J Gynaecol
Obstet. 143:22–36. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li X, Xia L, Chen X, Fu Y and Wu X: Simple
conization and pelvic lymphadenectomy in early-stage cervical
cancer: A retrospective analysis and review of the literature.
Gynecol Oncol. 158:231–235. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Landoni F, Maneo A, Zapardiel I, Zanagnolo
V and Mangioni C: Class I versus class III radical hysterectomy in
stage IB1-IIA cervical cancer. A prospective randomized study. Eur
J Surg Oncol. 38:203–209. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gopalani SV, Janitz AE and Campbell JE:
Cervical cancer incidence and mortality among Non-Hispanic African
American and white women, United States, 1999–2015. J Natl Med
Assoc. 112:632–638. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lott BE, Trejo MJ, Baum C, McClelland DJ,
Adsul P, Madhivanan P, Carvajal S, Ernst K and Ehiri J:
Interventions to increase uptake of cervical screening in
Sub-Saharan Africa: A scoping review using the Integrated
Behavioral Model. BMC Public Health. 20:6542020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
International agency for research on
cancer, . Cervix uteri fact sheet. 2020.https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sheet.pdfOctober
28–2021
|
|
20
|
Aylward J Global burden of cervical
cancer, . In TogetHER for Health. 2021.https://togetherforhealth.org/global-burden-cervical-cancer/November
28–2021
|
|
21
|
Keenan M: Human Development Index (HDI).
Salem Press Encyclopedia. 2021.https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,sso&db=ers&AN=98402115&site=eds-liveSeptember
28–2021
|
|
22
|
Arbyn M, Weiderpass E, Bruni L, de Sanjosé
S, Saraiya M, Ferlay J and Bray F: Estimates of incidence and
mortality of cervical cancer in 2018: A worldwide analysis. Lancet
Glob Health. 8:e191–e203. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Burton-Jeangros C, Cullati S, Manor O,
Courvoisier DS, Bouchardy C and Guessous I: Cervical cancer
screening in Switzerland: Cross-sectional trends (1992–2012) in
Social Inequalities. Eur J Public Health. 27:167–173.
2017.PubMed/NCBI
|
|
24
|
Lam JO, Lim WY, Chow KY and D'Souza G:
Incidence, trends and ethnic differences of oropharyngeal, anal and
cervical cancers: Singapore, 1968–2012. PLoS One. 10:e01461852015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Garau M, Musetti C, Alonso R and Barrios
E: Trends in cancer incidence in Uruguay: 2002–2015. Colomb Med
(Cali). 50:224–238. 2019.PubMed/NCBI
|
|
26
|
Gopalani S, Janitz A and Campbell J:
Cervical Cancer Incidence and Mortality among Non-Hispanic African
American and White Women, United States, 1999–2015. J Natl Med
Assoc. 112:632–638. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lott B, Trejo M, Baum C, McClelland D,
Adsul P, Madhivanan P, Carvajal S, Ernst K and Ehiri J:
Interventions to increase uptake of cervical screening in
sub-Saharan Africa: A scoping review using the integrated
behavioral model. BMC Public Health. 20:6542020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lekoane K, Kuupiel D, Mashamba-Thompson T
and Ginindza T: Evidence on the prevalence, incidence, mortality
and trends of human papilloma virus-associated cancers in
Sub-Saharan Africa: Systematic scoping review. BMC Cancer.
19:5632019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kisling LA: Prevention strategies.
StatPearls. 2021.https://www.ncbi.nlm.nih.gov/books/NBK537222/September
15–2021
|
|
30
|
Von Karsa L, Arbyn M, De Vuyst H, Dillner
J, Dillner L, Franceschi S, Patnick J, Ronco G, Segnan N, Suonio E,
et al: European guidelines for quality assurance in cervical cancer
screening. Summary of the supplements on HPV screening and
vaccination. Papillomavirus Res. 1:22–31. 2015. View Article : Google Scholar
|
|
31
|
Banday A, Jeelani S and Hruby V: Cancer
vaccine adjuvants-recent clinical progress and future perspectives.
Immunopharmacol Immunotoxicol. 37:1–11. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bogani G, Leone Roberti Maggiore U,
Signorelli M, Martinelli F, Ditto A, Sabatucci I, Mosca L, Lorusso
D and Raspagliesi F: The role of human papillomavirus vaccines in
cervical cancer: Prevention and treatment. Crit Rev Oncol Hematol.
122:92–97. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bosch F, Robles C, Díaz M, Arbyn M,
Baussano I, Clavel C, Ronco G, Dillner J, Lehtinen M, Petry K, et
al: HPV-FASTER: Broadening the scope for prevention of HPV-related
cancer. Nat Rev Clin Oncol. 13:119–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cuzick J and Wheeler C: Need for expanded
HPV genotyping for cervical screening. Papillomavirus Res.
2:112–115. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bruni L, Saura-Lázaro A, Montoliu A,
Brotons M, Alemany L, Diallo MS, Afsar OZ, Lamontagne DS, Mosina L,
Contreras M, et al: HPV vaccination introduction worldwide and WHO
and UNICEF estimates of national HPV immunization coverage
2010–2019. Prev Med. 144:1063992021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Siu J, Fung T and Leung L: Social and
cultural construction processes involved in HPV vaccine hesitancy
among Chinese women: A qualitative study. Int J Equity Health.
18:1472019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Termrungruanglert W, Khemapech N,
Vasuratna A, Havanond P, Deebukkham P, Kulkarni A and Pavelyev A:
The epidemiologic and economic impact of a quadrivalent human
papillomavirus vaccine in Thailand. PLoS One. 16:e02458942021.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Daley E, Vamos C, Zimet G, Rosberger Z,
Thompson E and Merrell L: The Feminization of HPV: Reversing gender
biases in US Human papillomavirus vaccine policy. Am J Public
Health. 106:983–984. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Daley E, Vamos C, Thompson E, Zimet G,
Rosberger Z, Merrell L and Kline N: The feminization of HPV: How
science, politics, economics and gender norms shaped U.S. HPV
vaccine implementation. Papillomavirus Res. 3:142–148. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Patel C, Brotherton J, Pillsbury A,
Jayasinghe S, Donovan B, Macartney K and Marshall H: The impact of
10 years of human papillomavirus (HPV) vaccination in Australia:
What additional disease burden will a nonavalent vaccine prevent?
Euro Surveill. 23:17007372018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chidyaonga-Maseko F, Chirwa M and Muula A:
Underutilization of cervical cancer prevention services in low and
middle income countries: A review of contributing factors. Pan Afr
Med J. 21:2312015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jaiswal J, LoSchiavo C, Maiolatesi A,
Kapadia F and Halkitis P: Misinformation, Gendered perceptions, and
low healthcare provider communication around HPV and the HPV
vaccine among young sexual minority Men in New York City: The P18
cohort study. J Community Health. 45:702–711. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Morris M, Friedemann Smith C, Boxell E,
Wardle J, Simon A and Waller J: Quantitative evaluation of an
information leaflet to increase prompt help-seeking for
gynaecological cancer symptoms. BMC Public Health. 16:3742016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Okan Y, Petrova D, Smith S, Lesic V and
Bruine de Bruin W: How do Women interpret the NHS information
leaflet about cervical cancer screening? Med Decis Making.
39:738–754. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kolthoff S, Hestbech M, Jørgensen K and
Brodersen J: Do invitations for cervical screening provide
sufficient information to enable informed choice? A cross-sectional
study of invitations for publicly funded cervical screening. J R
Soc Med. 109:274–281. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ngu S, Wei N, Kwan T, Chu M, Tse K, Chan K
and Ngan H: Impact of different educational interventions on
psychosocial well-being of women with a positive high-risk human
papillomavirus and normal cervical cytology: A randomised trial. J
Psychosom Obstet Gynaecol. 39:146–155. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Calderón-Mora J, Byrd TL, Alomari A,
Salaiz R, Dwivedi A, Mallawaarachchi I and Shokar N: Group versus
individual culturally tailored and theory-based education to
promote cervical cancer screening among the underserved Hispanics:
A cluster randomized trial. Am J Health Promot. 34:15–24. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Clavé Llavall A, de Wildt G, Meza G,
Tattsbridge J and Jones L: Nurses' and teachers' perceived barriers
and facilitators to the uptake of the human papilloma virus (HPV)
vaccination program in Iquitos, Peru: A qualitative study. PLoS
One. 16:e02552182021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Catarino R, Petignat P, Dongui G and
Vassilakos P: Cervical cancer screening in developing countries at
a crossroad: Emerging technologies and policy choices. World J Clin
Oncol. 6:281–290. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tranberg M, Bech B, Blaakær J, Jensen J,
Svanholm H and Andersen B: Preventing cervical cancer using HPV
self-sampling: Direct mailing of test-kits increases screening
participation more than timely opt-in procedures-a randomized
controlled trial. BMC Cancer. 18:2732018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Maver P and Poljak M: Primary HPV-based
cervical cancer screening in Europe: Implementation status,
challenges, and future plans. Clin Microbiol Infect. 26:579–583.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Woronoff A, Molinié F and Trétarre B:
Implementation of national cervical cancer screening program in
France. Bull Cancer. 106:253–261. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
De Prez V, Jolidon V, Willems B, Cullati
S, Burton-Jeangros C and Bracke P: Cervical cancer (over)screening
in Belgium and Switzerland: Trends and social inequalities. Eur J
Public Health. 30:410–415. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Watson M, Benard V and Flagg E: Assessment
of trends in cervical cancer screening rates using healthcare
claims data: United States, 2003–2014. Prev Med Rep. 9:124–130.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Landy R, Sasieni PD, Mathews C, Wiggins
CL, Robertson M, McDonald YJ, Goldberg DW, Scarinci IC, Cuzick J
and Wheeler CM; New Mexico HPV Pap Registry Steering Committee, :
Impact of screening on cervical cancer incidence: A
population-based case-control study in the United States. Int J
Cancer. 147:887–896. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Landy R, Mathews C, Robertson M, Wiggins
CL, Mcdonald YJ, Goldberg DW, Scarinci IC, Cuzick J, Sasieni PD and
Wheeler CM: A state-wide population-based evaluation of cervical
cancers arising during opportunistic screening in the United
States. Gynecol Oncol. 159:344–353. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sankaranarayanan R, Nene B, Shastri S,
Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R,
Kothari A, et al: HPV screening for cervical cancer in rural India.
N Engl J Med. 360:1385–1394. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Dorji T, Tshomo U, Gyamtsho S, Tamang S,
Wangmo S and Pongpirul K: Gender-neutral HPV elimination, cervical
cancer screening, and treatment: Experience from Bhutan. Int J
Gynaecol Obstet. Apr 30–2021.(Epubs ahead of print). doi:
10.1002/ijgo.13728. PubMed/NCBI
|
|
59
|
Kim JJ, Campos NG, Sy S, Burger EA, Cuzick
J, Castle PE, Hunt WC, Waxman A and Wheeler CM; New Mexico HPV Pap
Registry Steering Committee, : Inefficiencies and High-value
improvements in U.S. Cervical cancer screening practice. Ann
Internal Med. 163:589–597. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Singh U, Anjum, Qureshi S, Negi N, Singh
N, Goel M and Srivastava K: Comparative study between liquid-based
cytology & conventional Pap smear for cytological follow up of
treated patients of cancer cervix. Indian J Med Res. 147:263–267.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Karimi-Zarchi M, Peighmbari F, Karimi N,
Rohi M and Chiti Z: A Comparison of 3 ways of conventional pap
smear, liquid-based cytology and colposcopy vs cervical biopsy for
early diagnosis of premalignant lesions or cervical cancer in women
with abnormal conventional pap test. Int J Biomed Sci. 4:205–210.
2013.PubMed/NCBI
|
|
62
|
Ramírez-Palacios P, Chen A, Flores YN,
Crespi CM, Lazcano-Ponce E, Alvarez-Escobedo D, Torres-Ibarra L,
Rivera-Paredez B, León-Maldonado L, Hernández-López R, et al:
Benefit of double-reading cytology smears as a triage strategy
among high-risk human papillomavirus-positive women in Mexico.
Cancer Cytopathol. 128:715–724. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Lee H, Kang Y and Ju W: Cervical cancer
screening in developing countries: Using visual inspection methods.
Clin J Oncol Nurs. 20:79–83. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Orang'o E, Wachira J, Asirwa F, Busakhala
N, Naanyu V, Kisuya J, Otieno G, Keter A, Mwangi A and Inui T:
Factors associated with uptake of visual inspection with acetic
Acid (VIA) for cervical cancer screening in western Kenya. PLoS
One. 11:e01572172016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kudva V, Prasad K and Guruvare S: Andriod
device-based cervical cancer screening for resource-poor settings.
J Digital Imaging. 31:646–654. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Koliopoulos G, Nyaga V, Santesso N, Bryant
A, Martin-Hirsch P, Mustafa R, Schünemann H, Paraskevaidis E and
Arbyn M: Cytology versus HPV testing for cervical cancer screening
in the general population. Cochrane Database Syst Rev.
8:CD0085872017.PubMed/NCBI
|
|
67
|
Arbyn M, Simon M, Peeters E, Xu L, Meijer
CJLM, Berkhof J, Cuschieri K, Bonde J, Ostrbenk Vanlencak A, Zhao
F, et al: 2020 list of human papillomavirus assays suitable for
primary cervical cancer screening. Clin Microbiol Infect.
27:1083–1095. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ronco G, Dillner J, Elfström KM, Tunesi S,
Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi
P, et al: Efficacy of HPV-based screening for prevention of
invasive cervical cancer: Follow-up of four European randomised
controlled trials. Lancet. 383:524–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Castle PE, Pierz AJ, Adcock R, Aslam S,
Basu P, Belinson J, Cuzick J, El-Zein M, Ferreccio C, Firnhaber C,
et al: A pooled analysis to compare the clinical characteristics of
human papillomavirus-positive and -negative cervical precancers.
Cancer Prev Res. 13:829–840. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Reid JL, Wright TC, Stoler MH, Cuzick J,
Castle PE, Dockter J, Getman D and Giachetti C: Human
papillomavirus oncogenic mRNA testing for cervical cancer
screening. Am J Clin Pathol. 144:473–483. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Cuzick J, Cadman L, Ahmad AS, Ho L, Terry
G, Kleeman M, Lyons D, Austin J, Stoler MH, Vibat CRT, et al:
Performance and diagnostic accuracy of a urine-based human
papillomavirus assay in a referral population. Cancer Epidemiol
Biomarkers Prev. 26:1053–1059. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Torres-Ibarra L, Lazcano-Ponce E, Franco
EL, Cuzick J, Hernandez-Avila M, Lorincz A, Rivera B, Ramírez P,
Mendiola-Pastrana I, Rudolph S, et al: Triage strategies in
cervical cancer detection in Mexico: Methods of the FRIDA study.
Salud Publica Mex. 58:197–210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Torres-Ibarra L, Cuzick J, Lorincz AT,
Spiegelman D, Lazcano-Ponce E, Franco E, Moscicki A, Mahmud S,
Wheeler C, Rivera-Paredez B, et al: Comparison of HPV-16 and HPV-18
genotyping and cytological testing as triage testing within human
papillomavirus-based screening in Mexico. JAMA Netw Open.
2:e19157812019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cuzick J, Du R, Adcock R, Kinney W, Joste
N, McDonald R, English K, Torres S, Saslow D and Wheeler C; New
Mexico HPV Pap Registry Steering Committee, : Uptake of co-testing
with HPV and cytology for cervical screening: A population-based
evaluation in the United States. Gynecol Oncol. 162:555–559. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Kyrgiou M, Arbyn M, Bergeron C, Bosch F,
Dillner J, Jit M, Kim J, Poljak M, Nieminen P, Sasieni P, et al:
Cervical screening: ESGO-EFC position paper of the European Society
of Gynaecologic Oncology (ESGO) and the European Federation of
Colposcopy (EFC). Br J Cancer. 123:510–517. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Castle PE, Adcock R, Cuzick J, Wentzensen
N, Torrez-Martinez N, Torres S, Stoler M, Ronnett B, Joste N,
Darragh T, et al: Relationships of p16 immunohistochemistry and
other biomarkers with diagnoses of cervical abnormalities:
Implications for LAST terminology. Arch Pathol Lab Med.
144:725–734. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Macedo AC, Gonçalves JC, Bavaresco DV,
Grande AJ, Chiaramonte Silva N and Rosa MI: Accuracy of mRNA HPV
tests for triage of precursor lesions and cervical cancer: A
systematic review and meta-analysis. J Oncol. 2019:69350302019.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Shah UJ, Nasiruddin M, Dar SA, Khan MK,
Akhter MR, Singh N, Rabaan AA and Haque S: Emerging biomarkers and
clinical significance of HPV genotyping in prevention and
management of Cervical Cancer. Microb Pathog. 143:1041312020.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
van Leeuwen RW, Oštrbenk A, Poljak M, van
der Zee AG, Schuuring E and Wisman GB: DNA methylation markers as a
triage test for identification of cervical lesions in a high risk
human papillomavirus positive screening cohort. Int J Cancer.
144:746–754. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Tian Y, Yuan Wu NY, Liou YL, Yeh CT, Cao
L, Kang YN, Wang HJ, Li Y, Chu TY, Li W, et al: Utility of gene
methylation analysis, cytological examination, and HPV-16/18
genotyping in triage of high-risk human papilloma virus-positive
women. Oncotarget. 8:62274–62285. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Banila C, Lorincz AT, Scibior-Bentkowska
D, Clifford GM, Kumbi B, Beyene D, Wheeler CM, Cuschieri K, Cuzick
J and Nedjai B: Clinical performance of methylation as a biomarker
for cervical carcinoma in situ and cancer diagnosis: A worldwide
study. Int J Cancer. 150:290–302. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Cook DA, Krajden M, Brentnall AR, Krajden
M, Gondara L, Chan T, Law J, Smith L, Niekerk D, Ogilvie G, et al:
Evaluation of a validated methylation triage signature for human
papillomavirus positive women in the HPV FOCAL cervical cancer
screening trial. Int J Cancer. 144:2587–2595. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Louvanto K, Franco EL, Ramanakumar AV,
Vasiljević N, Scibior-Bentkowska D, Koushik A, Cuzick J, Coutlée F
and Lorincz AT; Biomarkers of Cervical Cancer Risk Study Team, :
Methylation of viral and host genes and severity of cervical
lesions associated with human papillomavirus type 16. Int J Cancer.
136:E638–E645. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Vale D, Teixeira J, Bragança J, Derchain
S, Sarian L and Zeferino L: Elimination of cervical cancer in low-
and middle-income countries: Inequality of access and fragile
healthcare systems. Int J Gynecol Obstet. 152:7–11. 2020.
View Article : Google Scholar
|
|
85
|
Ngwalle EW, Mgaya HN, Mpanju-Shumbusho W,
Chirenje ZM, Kirumbi L, Lebelle T and Kaggwa S: Situation analysis
for diagnosis and treatment of cervical cancer in mainland
Tanzania. East Afr Med J. 78:60–64. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Rosser JI, Hamisi S, Njoroge B and Huchko
MJ: Barriers to cervical cancer screening in rural Kenya:
Perspectives from a provider survey. J Community Health.
40:756–761. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
McDonald YJ, Goldberg DW, Scarinci IC,
Castle PE, Cuzick J, Robertson M and Wheeler CM: Health Service
Accessibility and risk in cervical cancer prevention: Comparing
rural versus nonrural residence in New Mexico. J Rural Health.
33:382–392. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Bingham A, Bishop A, Coffey P, Winkler J,
Bradley J, Dzuba I and Agurto I: Factors affecting utilization of
cervical cancer prevention services in low-resource settings. Salud
Publica Mex. 45 (Suppl 3):S408–S416. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Markovic M, Kesic V, Topic L and Matejic
B: Barriers to cervical cancer screening: A qualitative study with
women in Serbia. Soc Sci Med. 61:2528–2535. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Urasa M and Darj E: Knowledge of cervical
cancer and screening practices of nurses at a regional hospital in
Tanzania. Afr Health Sci. 11:48–57. 2011.PubMed/NCBI
|
